Related Experiment Videos
Treating the wheezing infant
Ronina A Covar1, Joseph D Spahn
1The Ira J. and Jacqueline Neimark Laboratory of Clinical Pharmacology and the Division of Allergy and Clinical Immunology, Department of Pediatrics, 1400 Jackson Street (A-303) Denver CO 80206, USA. covarr@njc.org
Insights
Managing asthma in young children presents unique challenges. Early intervention with controller therapy may alter disease course, but criteria for identifying suitable patients require further research.
Area of Science:
- Pediatric Pulmonology
- Asthma Management
- Childhood Respiratory Diseases
Background:
- Asthma management in infants and young children is complex due to age-specific challenges.
- Diagnosing asthma in this population is difficult due to limitations in objective lung function and inflammation measures.
- Identifying children who benefit from early controller therapy is crucial for potentially altering disease trajectory.
Purpose of the Study:
- To highlight the challenges in diagnosing and managing asthma in infants and young children.
- To emphasize the need for research into early intervention strategies for infantile asthma.
- To identify key areas requiring further investigation in pediatric asthma pharmacotherapy.
Main Methods:
- The abstract discusses the diagnostic and therapeutic challenges based on existing knowledge.
- It calls for large prospective studies to evaluate early pharmacologic interventions.
- It reviews the current limitations in approved medications and the need for long-term drug evaluations.
Main Results:
- There is a lack of established criteria to identify infants and young children who would benefit from early controller therapy.
- Current research is insufficient to guide the optimal use of medications, delivery methods, and monitoring for infantile asthma.
- Long-term studies on approved medications like inhaled glucocorticoids, long-acting beta-agonists (LABAs), and leukotriene modifiers in young children are lacking.
Conclusions:
- Further large-scale prospective studies are essential to determine the impact of early pharmacologic intervention on the natural history of infantile asthma.
- More research is needed to establish criteria for identifying patients likely to benefit from early controller therapy.
- Investigation into appropriate medications, delivery methods, and monitoring strategies for pediatric asthma is critical.
Abstract:
The management of infants and small children with asthma is a challenging task because of the many issues unique to this age group that deserve special consideration. The diagnosis of asthma is limited by inherent difficulties in obtaining objective measures of lung function and airway inflammation. In persistently symptomatic patients, the decision to initiate controller therapy is not as great an issue as it is in infants and young children with recurrent episodic wheeze in whom early intervention may allow a window of opportunity potentially to alter the course of the disease. The reality is that even if atopy has been consistently implicated in the development of persistent asthma, there is not a well-established set of criteria by which patients who are likely to benefit from early intervention controller therapy can be identified. Hence, large prospective studies need to be performed evaluating the impact of early pharmacologic intervention on the natural history of infantile asthma. Many areas needing investigation involve what medications to use, how best to deliver the medications, and how to monitor the response to treatment. Only a few medications have been approved for use in this population. Long-term studies evaluating available drugs such as inhaled glucocorticoids, LABAs, and the leukotriene-modifying agents in young children still need to be performed.